Kallyope lands $112 million Series C to ride the gut-brain axis for another 3 years
Five years after their launch, Kallyope and the gut-brain axis are headed to the clinic — and they’re getting a new fire hose of cash to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
